Effects of the angiotensin AT1 receptor blocker candesartan on myocardial ischemic/reperfusion injury

Journal of the American Society of Nephrology

Volumn 10, Issue 1 SUPPL. 11, 1999, Pages

  Shimizu, Masafumi ^b   Sjöquist, Per Ove ^a   Wang, Qing Dong ^b   Rydén, Lars ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIOXIDANT; CANDESARTAN; FELODIPINE; H 290 51; LOSARTAN; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; BENZIMIDAZOLE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; H290 51; H290-51; INDOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; REGIONAL PERFUSION; REPERFUSION INJURY; SWINE; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; FEMALE; HEMODYNAMICS; IN VITRO STUDY; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIOXIDANTS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FELODIPINE; FEMALE; HEMODYNAMIC PROCESSES; INDOLES; LOSARTAN; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; SWINE; TETRAZOLES;

EID: 17144466926     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hearse DJ, Bolli R: Reperfusion induced injury: Manifestations, mechanisms, and clinical relevance. Cardiovasc Res 26: 101-108, 1992
2. Matsumura K, Jeremy R, Schaper J, Becker LC: Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 97: 795-804, 1998
3. Opie LH: Role of calcium and other ions in reperfusion injury. Cardiovasc Drug Ther 5: 237-248, 1991
4. Massoudy P, Becker BF, Seligmann C, Gerlach E: Pre-ischaemic as well postischaemic application of a calcium antagonist affords cardioprotection in the isolated guinea pig heart. Cardiovasc Res 29: 577-582, 1995
5. Hatori N, Haga Y, Sjöquist P-O, Nordlander M, Rydén L: Coronary venous retroinfusion of felodipine reduces myocardial necrosis after coronary occlusion and reperfusion. J Cardiovasc Pharmacol 22: 160-166, 1993
6. Sjöquist P-O, Carlsson L, Jonason G, Marklund SL, Abrahamsson T: Cardioprotective effects of recombinant human extracellular-superoxide dismutase type C in isolated rat heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol 17: 678-683, 1991
7. Shimizu M, Wang Q-D, Sjöquist P-O, Rydén L: The lipid peroxidation inhibitor H290/51 protects myocardium from ischemia/reperfusion injury. Free Radic Biol Med 24: 726-731, 1998
8. Grinstead WC, Young JB: The myocardial renin-angiotensin system: Existence, importance, and clinical implications. Am Heart J 123: 1039-1045, 1992
9. Martorana P, Kettenbach B, Breipohl G, Linz W, Schölkens BA: Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by bradykinin antagonist. Eur J Pharmacol 182: 395-396, 1990
10. Werrmann JG, Cohen SM: Use of losartan to examine the role of the cardiac renin-angiotensin system in myocardial dysfunction during ischemia and reperfusion. J Cardiovasc Pharmacol 27: 177-182, 1996
11. Ford WR, Clanachan AS, Jugdutt BI: Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 94: 3087-3089, 1996
12. Yang BC, Phillips MI, Ambuehl PEJ, Shen LP, Mehta P, Mehta J: Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts. Circulation 96: 922-926, 1997
13. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT: Cardiac myocyte necrosis induced by angiotensin II. Circ Res 69: 1185-1195, 1991
14. Senzaki H, Gluzband YA, Pak PH, Crow MT, Janicki JS, Kass DA: Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II. Circ Res 82: 503-512, 1998
15. Mochizuki T, Eberli FR, Apstein CS, Lorell BH: Exacerbation of ischemic dysfunction by angiotensin II in red cell-perfused rabbit hearts. J Clin Invest 89: 490-498, 1992
16. Bermann MA, Walsh MF, Sowers JR: Angiotensin-II biochemistry and physiology: update on angiotensin-II receptor blockers. Cardiovasc Drug Rev 15: 75-100, 1997
17. Kinugawa K, Kohmoto O, Serizawa T, Takahashi T: CV-11974: A nonpeptide angiotensin II type 1 receptor antagonist. Cardiovasc Drug Rev 15: 59-74, 1997
18. Theroux P, Ross J Jr, Franklin D, Covel JW, Bloor CM, Sasayama S: Regional myocardial function and dimension early and late after myocardial infarction in the unanesthetized dog. Circ Res 40: 158-165, 1977
19. Heymann MA, Payne BD, Hoffman JE, Rudolph AM: Blood flow measurement with radionucleotide-labelled particles. Prog Cardiovasc Res 20: 55-79, 1977
20. Sjöquist P-O, Duker G, Almgren O: Distribution of the collateral blood flow at the lateral border of the ischemic myocardium after acute coronary occlusion in the pig and the dog. Basic Res Cardiol 79: 164-175, 1984
21. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tani T, Yanagi S, Toda T, Teragaki M, Akioka K, Takegichi K, Takeda T: Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV 116 on ischemia-reperfusion injury. Am Heart J 128: 1-6, 1994
22. Ferrario CM, Flack JM: Pathologic consequences of increased angiotensin II activity. Cardiovasc Drugs Ther 10: 511-518, 1996
23. 2-receptors in endothelial cells and isolated ischemic rat heart. Pharm Pharmacol Lett 3: 24-27, 1993